Pacira BioSciences (NASDAQ:PCRX) Given New $30.00 Price Target at Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX) had its price target increased by Needham & Company LLC from $22.00 to $30.00 in a research report sent to investors on Monday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on PCRX. Jefferies Financial Group lifted their price objective on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Royal Bank of Canada lifted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Finally, Barclays reduced their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $24.30.

Pacira BioSciences Stock Up 2.4 %

PCRX stock opened at $21.13 on Monday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $34.01. The company has a fifty day simple moving average of $18.37 and a 200 day simple moving average of $17.55. The firm has a market cap of $975.64 million, a PE ratio of -10.41 and a beta of 0.76.

Institutional Trading of Pacira BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in Pacira BioSciences in the second quarter valued at about $113,000. Canada Pension Plan Investment Board bought a new stake in Pacira BioSciences in the second quarter valued at about $140,000. Virtus Investment Advisers Inc. acquired a new position in Pacira BioSciences in the third quarter valued at about $98,000. CWM LLC boosted its position in Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after buying an additional 3,404 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.